Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
about
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibVascular Complications of Cancer ChemotherapyAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisCardiovascular disease in adult survivors of childhood cancer.High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis.Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Toward a Cancer Drug of Fungal OriginRisk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Drug target identification using network analysis: Taking active components in Sini decoction as an example.Cancer and Its Association With the Development of Coronary Artery Calcification: An Assessment From the Multi-Ethnic Study of AtherosclerosisCardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Emerging paradigms in cardiomyopathies associated with cancer therapies.Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.Ramucirumab: A Review in Advanced Gastric Cancer.Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Late Cardiotoxicity: Issues for Childhood Cancer Survivors.The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?Cardio-oncology: it takes two to translate.Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients.Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.Use of Antihypertensive Drugs in Neoplastic Patients.Lung cancer as a cardiotoxic state: a review.Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case reportPonatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation
P2860
Q26765210-F1341F25-117D-4DB3-9D23-A3588FF76A30Q26766269-D482E9F7-BA76-4A0C-8A33-9B589D9191BFQ28397726-58D13119-DCA1-40AA-AD12-62A853CE1F07Q34042984-1C32D1C4-D50D-4155-955B-2CB316DA0CA3Q34496687-32578FB2-1A5F-4C70-BE05-4D11405DE33EQ34943606-F94A9DB9-9048-4C61-94D3-B34A1174B654Q35562745-ED95F4B0-E312-4319-9568-2C5EAD55FCDFQ35596957-14C3B540-F62D-4710-8109-43040115B05EQ35691234-12CC4E99-B77F-4340-8750-A254776CD700Q36051199-64369E55-3569-42C9-B817-5C2BB8A00722Q36316309-FA199EC8-5C52-4AF7-9168-9D9421C202F7Q36814771-4914DF6E-3723-462A-B7EC-A35D399EF155Q36836294-D64B08DA-B455-4EBE-B8E4-24AB5A0063CCQ36891574-F6733716-7646-40A3-AE7B-4ECA4073F2B6Q37729290-15433190-85BD-478A-BE56-9D70A79F5FE1Q38132645-08F1B1EE-85B0-4B99-8F5E-027EAD30BB74Q38204169-9164F91C-05C9-4673-832F-EEB76DC07D83Q38581171-671CF1A6-1F3F-4C25-B2B0-6CB825ABBEB1Q38823143-07C54819-57FC-4F56-ADE4-439673FF16F8Q38845457-E102C04C-06E8-43A0-B0E4-071C60A455D5Q38904546-62D0F72A-8E67-49C9-83AF-22B2BFC84A17Q40990867-48192E01-98A2-4A8F-8B50-6F9D27386752Q44228500-2040BF5D-D58D-4484-BD60-50DF95E21175Q46562954-F14F66DA-B9C6-48D4-B985-B472DBEBD6FCQ47681122-21A4C867-7120-411B-8108-C1F43CD17D62Q48274997-1E079BBB-CC47-415C-B941-273E3A476E3BQ48342585-A1A26BAD-0943-4B30-AB08-201603BCD3F0Q53117997-CB6CB832-CDAF-4C9E-9B8A-F7CE7D6C7C34Q57809492-C9D29F21-D47C-4987-8359-4D23423E31DCQ58761411-3DA4AB4E-72A2-433F-A8B9-F2F16CA58BB6
P2860
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cardiovascular complications a ...... nce and evolving perspectives.
@en
type
label
Cardiovascular complications a ...... nce and evolving perspectives.
@en
prefLabel
Cardiovascular complications a ...... nce and evolving perspectives.
@en
P2093
P2860
P1476
Cardiovascular complications a ...... nce and evolving perspectives.
@en
P2093
Javid Moslehi
Steven M Bair
Toni K Choueiri
P2860
P304
P356
10.1016/J.TCM.2012.09.008
P577
2013-01-02T00:00:00Z